Triple-Negative Breast Cancer Clinical Trials in Fairfax, Virginia
15 recruitingFairfax, Virginia
Showing 1–15 of 15 trials
Recruiting
Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled46 locationsNCT05005403
Recruiting
Phase 1Phase 2
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Triple-Negative Breast CancerMelanomaNon-small Cell Lung Cancer+6 more
AstraZeneca60 enrolled13 locationsNCT07115043
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled350 locationsNCT05633654
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 1
A Study of LY4175408 in Participants With Advanced Cancer
Triple-Negative Breast CancerCarcinoma, Non-Small Cell LungNeoplasm Metastasis+2 more
Eli Lilly and Company240 enrolled27 locationsNCT07046923
Recruiting
Phase 1
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 1
A Study of XMT-1660 in Participants With Solid Tumors
Breast CancerTriple-Negative Breast CancerOvarian Cancer+4 more
Mersana Therapeutics319 enrolled26 locationsNCT05377996
Recruiting
Phase 1
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Triple-Negative Breast CancerColorectal, CancerNon-small Cell Lung Cancer+5 more
IDEAYA Biosciences150 enrolled5 locationsNCT07503808
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
Triple-Negative Breast CancerOvarian CancerAdvanced Solid Tumors+2 more
Accent Therapeutics90 enrolled5 locationsNCT06799065
Recruiting
Phase 1
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Breast CancerTriple-Negative Breast CancerEsophageal Cancer+9 more
SystImmune Inc.470 enrolled39 locationsNCT05983432
Recruiting
Phase 1
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Triple-Negative Breast CancerGastric CancerGastroesophageal-junction Cancer+9 more
Dren Bio96 enrolled10 locationsNCT06999187
Recruiting
Phase 1
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Triple-Negative Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Cancer+11 more
OncoNano Medicine, Inc.168 enrolled16 locationsNCT06022029
Recruiting
Phase 1Phase 2
Study of AVZO-021 in Patients With Advanced Solid Tumors
Endometrial CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+6 more
Avenzo Therapeutics, Inc.430 enrolled13 locationsNCT05867251
Recruiting
Phase 1
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Triple-Negative Breast CancerColorectal, CancerOvarian Cancer+1 more
Hefei TG ImmunoPharma Co., Ltd.38 enrolled2 locationsNCT05746897